4//SEC Filing
Barron Hal 4
Accession 0001209191-18-017798
CIK 0001594864other
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 6:14 PM ET
Size
16.9 KB
Accession
0001209191-18-017798
Insider Transaction Report
Form 4
Barron Hal
Director
Transactions
- Disposition to Issuer
Common Stock
2018-03-05$87.00/sh−3,780$328,860→ 0 total - Disposition to Issuer
Director Stock Option (Right to Buy)
2018-03-05$27.00/sh−12,000$324,000→ 0 totalExercise: $60.00Exp: 2025-06-11→ Common Stock (12,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2018-03-05$44.60/sh−12,000$535,200→ 0 totalExercise: $42.40Exp: 2026-06-16→ Common Stock (12,000 underlying) - Disposition from Tender
Common Stock
2018-03-05$87.00/sh−100,000$8,700,000→ 3,780 total - Disposition to Issuer
Director Stock Option (Right to Buy)
2018-03-05$80.64/sh−75,000$6,048,000→ 0 totalExercise: $6.36Exp: 2024-09-14→ Common Stock (75,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2018-03-05$63.71/sh−12,000$764,520→ 0 totalExercise: $23.29Exp: 2027-06-15→ Common Stock (12,000 underlying)
Footnotes (4)
- [F1]On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
- [F2]Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in note (3) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
- [F3]In accordance with their terms, RSUs held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such RSU and (ii) $87.00.
- [F4]In accordance with their terms, Options held by non-employee directors were converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such Option and (ii) $87.00 less the applicable exercise price.
Documents
Issuer
Juno Therapeutics, Inc.
CIK 0001594864
Entity typeother
Related Parties
1- filerCIK 0001418677
Filing Metadata
- Form type
- 4
- Filed
- Mar 6, 7:00 PM ET
- Accepted
- Mar 7, 6:14 PM ET
- Size
- 16.9 KB